BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
Northwestern University
Ohio State University
Dana-Farber Cancer Institute
Scripps Clinic
North Shore Long Island Jewish Health System
University of New Mexico
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01711632
First received: October 17, 2012
Last updated: May 8, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2016
  Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)